30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

More 2010 Results: ArthroCare

$244.4MM, +10%
* Sports Medicine $231.9MM, +11% (ex-U.S. +13%)
* Other (includes Spine) $12.4MM, -5%

4Q10 revenue:
$63.2MM, flat
* Sports Medicine $59.8MM, +1%
* Other (includes Spine) $3.4MM, -18%

* Spine Coblation “very healthy business” in Europe, where reimbursement is established
* $3.6MM 4Q revenue from Sports Med products contract manufactured for Smith & Nephew lower, as expected
* In Americas, 4Q proprietary Sport Med sales down slightly on soft procedure volumes, lower average sales price
* Modest market improvement sequentially in 4Q: active customers remained constant, while revenue per customer increased
* Now launching Titan and Spartan preloaded anchors in 2011, to complement FirstPass suture passing instrument
* Wants to tailor Coblation and fixation offerings for arthroscopic hip repair; in some cases has products, but lacks sufficient distribution
* Investing in collection of clinical evidence to support products such as Coblation to debride knee cartilage
* Little to no progress made with Department of Justice (DoJ) investigation
* Settled with SEC, fully resolved investigation of company from 7/08, no fines imposed (relative to restatement of company financials)
* Challenges for 2011: recorded $6.6MM in deferred revenue in 2010 that is not expected to return; revenue associated with contract manufacturing agreement with Smith & Nephew could be volatile; does not expect significant contribution from other products (including spine)